Drug Trial Radar · NCT03568929
Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
257
Actual
Start
May 25, 2018
Primary completion
Oct 29, 2021
Study completion Oct 29, 2021
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jun 26, 2018
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the overall safety profile of idelalisib monotherapy in patients with refractory follicular lymphoma (FL).
Conditions
- Follicular Non-Hodgkin's Lymphoma Refractory
Interventions
IdelalisibDrug
Tablets administered according to the product information and treatment guidelines in routine clinical practice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Safety Profile of Idelalisib as Measured by the Incidence of Adverse Events (AE), Serious AEs, Special Situation Reports, Adverse Drug Reactions (ADR), and Serious ADRsTime frame: 250 patient-years (8 months of treatment period, 3 years of retrospective time frame, and 2.5 years of prospective observation period)
Locations
88 sites in 10 countries. Site status is shown where the registry gives one.
Ziekenhuis Netwerk Antwerpen Stuivenberg Hospital
Antwerp, Belgium
Centre Hospitalier Universitaire d'Amiens (CHU d'Amiens) - Hopital Nord
Amiens, France
Centre Hospitalier Bourg-en-Bresse Fleyriat
Bourg-en-Bresse, France
Centre Hospitalier de Cannes
Cannes, France
Hôpital Privé Sévigné
Cesson-Sévigné, France
Centre Hospitalier Chalon sur Saône William Morey
Chalon-sur-Saône, France
Centre Hospitalier Universitaire Estaing
Clermont-Ferrand, France
CHU de Dijon
Dijon, France
Groupe Hospitalier Mutualiste de Grenoble - Institut Daniel Hollard
Grenoble, France
Clinique Victor Hugo
Le Mans, France
Centre Hospitalier Le Mans
Le Mans, France
Centre Hospitalier de Lens
Lens, France
Hôpital de la Conception
Marseille, France
Centre Hospitalier Régional d'Orléans
Orléans, France
Centre hospitalier de Perigueux
Pessac, France
Centre Hospitalier Lyon Sud
Pierre-Bénite, France
Centre Hospitalier Universitaire de Poitiers
Poitiers, France
Hopital Bretonneau, Centre Henri Kaplan
Tours, France
Klinikum Frankfurt Hochst
Frankfurt, Germany
Universitätsmedizin Göttingen
Göttingen, Germany
Klinikum Südstadt Rostock
Rostock, Germany
Gemeinschaftspraxis für Hämatologie und Onkologie Westerstede
Westerstede, Germany
University General Hospital of Alexandroupolis
Alexandroupoli, Greece
Athens Medical Center-Psychikon branch
Athens, Greece
Henry Dunant Hospital
Athens, Greece
University General Hospital of Patras
Pátrai, Greece
AHEPA University General Hospital of Thessaloniki
Thessaloniki, Greece
Saint James's Hospital
Dublin, Ireland
Mater Misericordiae University Hospital
Dublin, Ireland
Midland Regional Hospital - Mullingar
Mullingar, Ireland
Ospedali Riuniti di Ancona, Clinica Ematologica
Ancona, Italy
Ospedale Mazzoni
Ascoli Piceno, Italy
Azienda Ospedaliera Policlinico di Bari
Bari, Italy
Monsignor Raffaele Dimiccoli Hospital
Barletta, Italy
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Brescia, Italy
Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi
Catania, Italy
Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele
Catania, Italy
Ospedale di Civitanova Marche
Civitanova Marche, Italy
Azienda Ospedaliero - Universitaria Careggi
Florence, Italy
Presidio Ospedaliero di Livorno
Livorno, Italy
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.